SCHEMBL376528

SCHEMBL376528

CCCc1oc(-c2ccc(Cl)cc2)nc1CCC(=O)c1ccc(OC(C)(C)C(=O)O)cc1

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PPARA Q07869 16/20 0.55
PPARG P37231 12/20 0.55
PPARD Q03181 6/20 0.55
FABP2 P12104 2/20 0.47
SLC22A12 Q96S37 1/20 0.47
MEN1 O00255 1/20 0.46
CYP1A2 P05177 1/20 0.46
CYP3A4 P08684 1/20 0.46
CYP2D6 P10635 1/20 0.46
MAPT P10636 1/20 0.46
CYP2C19 P33261 1/20 0.46
KMT2A Q03164 1/20 0.46
ALDH1A1 P00352 2/20 0.44
SMN1; SMN2 Q16637 1/20 0.44
KDM4E B2RXH2 1/20 0.44
PKM P14618 1/20 0.44
PSEN1 P49768 3/20 0.43
PSEN2 P49810 3/20 0.43
APH1B Q8WW43 3/20 0.43
NCSTN Q92542 3/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL377238 0.90 PPARA (0.53) PPARAPPARGPPARDMEN1CYP1A2
SCHEMBL377204 0.83 HSD17B3 (0.43) PPARAMAPTALDH1A1KDM4E
SCHEMBL6696876 0.79 PPARA (0.76) PPARAPPARGPPARD
SCHEMBL5105781 0.79 PPARA (0.76) PPARAPPARGPPARD
SCHEMBL376784 0.77 PPARA (0.59) PPARAPPARGPPARD
SCHEMBL28624789 0.75 PPARA (0.68) PPARAPPARGPPARDFABP2SLC22A12
SCHEMBL6993359 0.73 PPARA (0.69) PPARAPPARGPPARD
SCHEMBL1765972 0.73 PPARA (0.69) PPARAPPARGPPARDFABP2SLC22A12
SCHEMBL6700759 0.71 PPARA (0.64) PPARAPPARGPPARD
SCHEMBL10653269 0.71 HSD17B10 (0.49) PPARAMAPTALDH1A1SMN1; SMN2KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1310494-B1 PPAR (delta) ACTIVATORS NIPPON CHEMIPHAR CO (JP) 2012-01-25 EP disclosed
US-6787552-B2 HYPERGLYCEMIA, HYPERLIPIDEMIA, OBESITY, SYNDROME X; OXAZOLE OR THIAZOLE OR IMIDAZOLE DERIVATIVES NIPPON CHEMIPHAR CO., LTD. (JP) 2004-09-07 US disclosed
US-20040097739-A1 Ppar delta activators NIPPON CHEMIPHAR CO., LTD. (JP) 2004-05-20 US disclosed
EP-1310494-A1 PPAR (delta) ACTIVATORS NIPPON CHEMIPHAR CO., LTD. (JP) 2003-05-14 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040097739-A1 Ppar delta activators PPARD, PPARG, PPARA PPARA 3/4885PPARG 2/4885PPARD 1/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.